Patents Assigned to Vanqua Bio, Inc.
  • SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF
    Publication number: 20250230172
    Abstract: Provided herein are compounds that modulate glucocerebrosidase (GCase), an enzyme whose activity is associated with neurological diseases and disorders (e.g., Gaucher's disease, Parkinson's disease). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating GCase-related diseases and disorders (e.g., Gaucher's disease, Parkinson's disease) with the compounds in a subject, by administering the compounds and/or compositions described herein.
    Type: Application
    Filed: October 12, 2022
    Publication date: July 17, 2025
    Applicant: Vanqua Bio, Inc.
    Inventors: Kevin Hunt, Jianbin Zheng, Sida Shen
  • SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF
    Publication number: 20250034170
    Abstract: Provided herein are compounds that modulate glucocerebrosidase (GCase), an enzyme whose activity is associated with neurological diseases and disorders (e.g., Gaucher's disease, Parkinson's disease). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating GCase-related diseases and disorders (e.g., Gaucher's disease, Parkinson's disease) with the compounds in a subject, by administering the compounds and/or compositions described herein.
    Type: Application
    Filed: October 12, 2022
    Publication date: January 30, 2025
    Applicant: Vanqua Bio, Inc.
    Inventors: Kevin Hunt, Jianbin Zheng, Sida Shen, Jeremiah Brittin, Zhiquan Lei, Greg Sheyka
  • OLIGONUCLEOTIDES FOR TARGETING COMPLEMENT C5
    Publication number: 20240417725
    Abstract: In some embodiments, the present disclosure provides compositions of antisense oligonucleotides (ASOs) such as gapmer ASOs for inhibition of complement C5 expression. Further, in some embodiments, such ASOs are useful for treating diseases associated with complement C5 dysfunction. Where a sequence is complementary to an intron of a complement 05 pre-mRNA.
    Type: Application
    Filed: October 12, 2022
    Publication date: December 19, 2024
    Applicant: Vanqua Bio, Inc.
    Inventors: Kevin Hunt, Maria Nguyen, Daniel Ysselstein, Carole Deyts
  • SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF
    Publication number: 20240262832
    Abstract: Provided herein are compounds that modulate glucocerebrosidase (GCase), an enzyme whose activity is associated with neurological diseases and disorders (e.g., Gaucher's disease. Parkinson's disease). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating GCase-related diseases and disorders (e.g., Gaucher's disease. Parkinson's disease) with the compounds in a subject, by administering the compounds and/or compositions described herein.
    Type: Application
    Filed: April 28, 2022
    Publication date: August 8, 2024
    Applicant: Vanqua Bio, Inc.
    Inventors: Kevin Hunt, Jianbin Zheng, Sida Shen
  • SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF
    Publication number: 20240246952
    Abstract: Provided herein are compounds that modulate glucocerebrosidase (GCase), an enzyme whose activity is associated with neurological diseases and disorders (e.g., Gaucher's disease, Parkinson's disease). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating GCase-related diseases and disorders (e.g., Gaucher's disease, Parkinson's disease) with the compounds in a subject, by administering the compounds and/or compositions described herein.
    Type: Application
    Filed: April 28, 2022
    Publication date: July 25, 2024
    Applicant: Vanqua Bio, Inc.
    Inventors: Kevin Hunt, Jianbin Zheng